An 11 year o l d g i r l presented with s b r t s t a t u r e . m n h y p p i tuitarism was diay nosed and replacement therapy was s t a r t e d with thyroxine, c o r t i s o l , and growth b m n e t r e a b w n t , which r e s u l t e d i n catch-up growth. CJe obtained the following hormonal d a t a : 1) undetectable growth b m n e s e c r e t i o n a f t e r aryinine-insulin ( C0.8 ng/ml) , 2 ) no p r o l a c t i n r i s e a f t e r ?RF and c h l o r p r m z i n e
( < 2 ng/ml); 3 ) no TSH r i s e a f t e r ?RF (<1.0 vILl/ml), 4 ) no LH, FSh r i s e a f t e r LKF. When LKF was given 0.025 ug/kg lV every 2 hours f o r 5 days (Valk, JCEM 53, 184, 1981) remained <3.5 rnlU/~nl and FSH was undetectable. A 5-3 ACM infusion caused a modest r i s e of plasma c o r t i s o l (<0.2 to 8.8 ug/dl), c o n s i s t e n t w i t h secondary adrenal insufficiency. m s t e r i o r p i t u i t a r y funct i o n and a d r e m d u l l a r y function were normal. T k thyroid responded normally to exogenous TSH. Aldosterone s e c r e t i o n increased upon upright posture and on a low s a l t d i e t . 9 t u l l radiography showed a shallow s e l l a t u r c i c a . e r e b r a 1 computed tomography d i d n o t i d e n t i f y the p i t u i t a r y gland and suggested h y p p l a s i a of the r i g h t c a r o t i d a r t e r y . This was confirmed by a a technetium scan of the brain, which s W asymmetric c e r e b r a l blood flow. Ih conclusion, t h i s p a t i e n t had biochemical and radiological evidence of absence of the p i t u i t a r y gland. Thus, a l t b u g h she survived without treatment u n t i l age 11, she appears to h v e the syndrome of congenital p i t u i t a r y a p l a s i a described by Blizzard ( J . Ed. 48, 782, 1956 ). P i t u i t a r y vascular insuff iciency is a p s s i b l e cause of t h i s p a t i e n t ' s p i t u i t a r y a p l a s i a . Adrenal CT was performed i n 12 p a t i e n t s . These CT s t u d i e s revealed massively macronodular, hyperplastic adrenals i n a 30-year-old p a t i e n t with untreated c l a s s i c a l CAH and markedly enlarged adrenals i n 4 p a t i e n t s with poorly t r e a t e d c l a s s i c a l CAH, while mildly hyperplastic adrenals were seen i n 4 of 7 p a t i e n t s with nonclassical (mild) CAH.
Thus, sonographic and CT examination of t h e adrenal glands exhibited unequivocal evidence of b i l a t e r a l adrenal hyperpl asi a i n c l a s s i c a l 21-OH def CAH, i n d i c a t i n g t h e usefulness of t h e s e s t u d i e s i n expediting t h e diagnosis of c l a s s i c a l CAH. However, t h e CT evaluation i n t h e nonclassical form of CAH i s not cons i s t e n t l y useful i n imaging adrenal hyperplasia. Previous data'revealed t h a t a v a r i e t y of mouge f e t a l t i s s u e s , with t h e exception of t h e placenta, a r e capable of producing IGF-I t h a t may a c t l o c a l l y t o r e g u l a t e f e t a l growth (D'Ercole, e t al., Dev. Biol. 75: 315, 1980) . Although the placenta is essent i a l f o r normal f e t a l development, l i t t l e i s known regarding the mechanisms c o n t r o l l i n g placental growth. Human placental explants were examined a t various s t a g e s of g e s t a t i o n f o r t h e a b i l i t y t o produce IGF-I i n organ c u l t u r e . The p l a c e n t a l explants were washed extensively and incubated i n serum-free media. The media was a c i d i f i e d and chromatographed over a Sephadex G-50 column t o separate t h e IGF-I from s p e c i f i c binding proteins. IGF-I was measured by s p e c i f i c radioimmunoassay (RIA). Placental t i s s u e from a l l g e s t a t i o n a l ages secreted immunoreactive IGF-I, 2.19*.35 ng./ mg. prot./48 h r s . (~e a n ' S.D.). There was no difference i n IGF-I production between pre-term (9-19wk.) and term placentae under these conditions. The a c t i v i t y was reduced >60% by 50 u M cyclohexamide, suggesting t h a t most of t h e a c t i v i t y was t h e r e s u l t of de novo protein synthesis. The s i m i l a r i t y of t h i s material t o a u t h e n t i c human IGF-I i s supported by p a r a l l e l displacement i n the RIA and co-elution on a Sephadex G-50 column. The human placenta contains s p e c i f i c IGF receptors. These d a t a demonstrate t h a t the human placenta is a l s o capable of producing IGF-I, t h a t may a c t l o c a l l y t o regulate placental growth. wed&udied 7 girls, dges 1.3 to 10 yrs., with precocious puberty associated with MAS. In 6 of the 7 girls, basal and LHRH-stimulated gonodotropins and bioactive LH were prepubertol.
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MECHANISM OF PRECOCIOUS PUBERTY IN GIRLS
WITH MCCUNE-ALBRIGHT SYNDROME (MAS
In one girl, gonodotropins and bioactive LH were in the pubertal range. Ovarian volumes (mean 6.4, range 1.4 -12.9 ml) were increased in all 7 girls compared to prepubertal girls (nl < 0.9 ml -Radiology 125:477(1977)).
The girls with MAS had greater asymmetry in ovorion volume than did girls with true precocious puberty (TPP) (R to L difference 5.9 5 1.9 ml vs. 1.5 + 0.2 ml in TPP; p <0.05). The logarithm of plasma estradiol correlated significontly with ovarian volume (p< 0.05). Ovarian volumes and plasma estradiol fluctuated markedly over time. LHRH-analog treatment, given t o 6 of the 7 girls, failed to suppress menses, ovarion cyst volume, or estradiol levels in the five girls who had low gonadotropins. The girl who hod true puberty responded to LHRH-analog treatment. She had a bone age of 13.5 years, which is within the range when puberty normally occurs. Thus, we cannot exclude the possibility that her gonadotropins were also low when secondary sex characteristics first appeared. We conclude that the mechanism of precocious puberty in the majority of girls with MAS is intermittent ovarion estrogen secretion independent of pubertal hypothalamic-pituitary activation.
ACCELERATION OF LINEAR GROWTH AFTER REPEATED DOSES
OF GROWTH HORMONE-RELEASING FACTOR (GRF ) .
Gelato, J u d i t h Levine Ross, Ora Pescovitz, Fernando Cassorla, M a w S k e r d a , P e n e l o p e -F & i i l T i i i , D. Lynn LoFia';ux,and Geor e R. M e r r 1 a m . m . by David Nelson). Dr8, NICHD, Bethesda. a m n t stimulators of GH secretion i n man. Ye administered 1 ug/kg GRF 1-44 NH2 t o 15 children with documented GH deficiency, ages 4-20 years. 12/15 had a measurable GH response. Following discontinuation of GH therapy f o r a t l e a s t 2 months, 2 responders and 1 nonresponder then received 1 vglkg GRF IV q 3 h f o r 10-12 d. Short-term growth was assessed by the lower l e g measurement technique of Valk e t a l . (Growth 47:53, 1983) . GH was measured q 20 min f o r 12 h on the l s t , and 5th or 7th days of multiple-dose therapy and f o r the f i r s t 12 hours o f f GRF. Somatomedin-C ( S K I l e v e l s were drawn d a i l y . Baseline GH l e v e l s were (0.7 ng/ml . In the 2 responders, mean peak GH response t o GRF increased, SmC rose, and lower l e g growth velo c i t y (GV) acceler,ated (Table) . GH l e v e l s returned t o base1 ine a f t e r GRF was stopped. The t h i r d p a t i e n t had no hormonal o r growth response.
Single Dose ---------Multiple Doses----------P t .
CA BA Peak GH Peak GH, ng/ml SmC, U/ml &V r s y r s ng/ml (0.7 (0.1 4 0 . 1 0 Thus most children with GH deficiency respond t o GRF, and mult i p l e doses of GRF can a c c e l e r a t e short-term l i n e a r growth. GRF may form the basis f o r an a l t e r n a t i v e treatment of GH deficiency. Sustained accelerated growth i s necessary f o r GH-deficient p a t i e n t s t o achieve normal mature heights. However, the catch-up growth seen during the i n i t i a l 12-18 mos of standard GH replacement Rx (0.3 U/kg/wk) does not p e r s i s t and few GH-treated children a t t a i n t h e i r f u l l p o t e n t i a l height. Previous s t u d i e s of the dose1 growth-response r e l a t i o n s h i p have been confined t o the i n i t i a l phase of Rx. To a s s e s s the e f f i c a c y and s a f e t y of higher doses, given when catch-up growth had ceased, we gave GH f o r 8 months a t 0.9Ulkglweek t o 8 GH-deficient children (7-12 yrs) e a r l i e r t r e a t & f o r 2-8 y r s with GH a t 0.3 Ulkglwk. Mean growth v e l o c i t y (GV) increased from 5.551.2 t o 9.722.5 cmlyr (pc.01). GV corrected f o r bone age was, as expected, normal on standard Rx and increased t o over 5 standard deviations above the mean on the higher dose. This acceleration represents a renewal of t r u e catch-up growth. Mean somatomedin C l e v e l s rose from 0 . 3 2 5 . 3 t o 0 . 9 5 5 . 9 U/ml (p<.05) a s GV increased. Glucose tolerance was barely affected by the dose increase, while the a r e a under the insu1i.n curve increased s l i g h t l y (1.35.5 t o 2.25.2 mU/ml.min; p=.17). Serum l i p i d l e v e l s were not adversely a f f e c t e d , f a s t i n g t r iglycerides f a l l i n g from 67234 t o 64+21 mgldl, while c h o l e s t e r o l , rose from 158+31 t o 166222 mgldl. There was no change i n the need f o r thyroid replacement, two p a t i e n t s had modest e l e v a t i o n s i n anti-GH antibody t i t e r s during high dose Rx. Improved supplies of GH may permit an upward revision i n dose recommendat i o n s f o r replacement Rx.
